Otros idiomas Intensity Therapeutics, Inc.

Acciones

INTS

US45828J1034

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 27/06/2024			Varia. Cinco días.	Varia. 1 de enero.
4,921 ^USD	-0,19 %		+5,37 %	-42,58 %

15/05	Intensity Therapeutics, Inc. nombra a Thomas Dubin miembro de la Junta Directiva	CI
10/05	Intensity Therapeutics, Inc. celebra un acuerdo de colaboración con el Grupo Suizo para la Investigación del Cáncer SAKK	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors	15/05
Intensity Therapeutics, Inc. Appoints Thomas Dubin to the Board of Directors	15/05
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe	13/05
Intensity Therapeutics, Inc. Enters into A Collaboration Agreement with the Swiss Group for Cancer Research SAKK	10/05
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial	10/05
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	10/05
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	10/05
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Intensity Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	19/04
Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors	19/04
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024	02/04
Portage biotech completes monetization of intensity therapeutics shares	27/03
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares	26/03
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024	14/03
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference	21/02
Intensity Therapeutics Gets FDA Green Light for Phase 3 Study	03/01
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program	03/01
Certain Common Stock of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	26/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Intensity Therapeutics, Inc.

Acciones

INTS

US45828J1034

Otros idiomas

Filtros